UCB — Investor Relations & Filings
UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 2021 UCB Integrated Annual Report - ENG.pdf | 2022-02-24 | English | |
| 2021 UCB Integrated Annual Report - FR_digi.pdf | 2022-02-24 | French | |
| 2021 UCB Integrated Annual Report - NL Final.pdf | 2022-02-24 | Dutch | |
| ucbsa-2021-12-31.html | 2022-02-24 | English | |
| ucbsa-2021-12-31.zip | 2022-02-24 | English | |
| ucbsa-2021-12-31 (FR).zip | 2022-02-24 | French |
Browse filings by year
18 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2022
15 filings
| |||||
| 3217177 | 2021 UCB Integrated Annual Report - ENG.pdf | 2022-02-24 | English | ||
| 3217175 | 2021 UCB Integrated Annual Report - FR_digi.pdf | 2022-02-24 | French | ||
| 3217174 | 2021 UCB Integrated Annual Report - NL Final.pdf | 2022-02-24 | Dutch | ||
| 3217172 | ucbsa-2021-12-31.html | 2022-02-24 | English | ||
| 3217170 | ucbsa-2021-12-31.zip | 2022-02-24 | English | ||
| 3217165 | ucbsa-2021-12-31 (FR).zip | 2022-02-24 | French | ||
| 3217161 | ucbsa-2021-12-31.html | 2022-02-24 | French | ||
| 3217155 | ucbsa-2021-12-31.html | 2022-02-24 | Dutch | ||
| 3217152 | ucbsa-2021-12-31 (NL).zip | 2022-02-24 | Dutch | ||
| 3217181 | 220218 - Disposals of own shares_ENG.pdf | 2022-02-18 | English | ||
| 3217179 | 220218 - Aliénation d'actions propres_FR.pdf | 2022-02-18 | French | ||
| 3217178 | 220218 - Vervreemding van eigen aandelen_NL.pdf | 2022-02-18 | Dutch | ||
| 3217186 | 220211 - Disposals of own shares_ENG.pdf | 2022-02-11 | English | ||
| 3217185 | 220211 - Aliénation d'actions propres_FR.pdf | 2022-02-11 | French | ||
| 3217182 | 220211 - Vervreemding van eigen aandelen_NL.pdf | 2022-02-11 | Dutch | ||
Financials
We couldn't load the financials
No data available yet
We have extracted financials for UCB, but not for this combination of statement and period. Try a different combination.
Swipe the table to view all periods, or rotate your phone for a wider view.
| Line item | ! |
|---|---|
| Definition not yet available — coming soon. |
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
UCB via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/4017/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=4017 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=4017 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=4017 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 4017}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for UCB (id: 4017)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.